CN104666373A - Novel use of Eurycoma longifolia Jack - Google Patents
Novel use of Eurycoma longifolia Jack Download PDFInfo
- Publication number
- CN104666373A CN104666373A CN201310612131.0A CN201310612131A CN104666373A CN 104666373 A CN104666373 A CN 104666373A CN 201310612131 A CN201310612131 A CN 201310612131A CN 104666373 A CN104666373 A CN 104666373A
- Authority
- CN
- China
- Prior art keywords
- eurycoma longifolia
- extract
- water
- eurycoma
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000005739 Eurycoma longifolia Species 0.000 title claims abstract description 154
- 239000000284 extract Substances 0.000 claims abstract description 111
- 239000012567 medical material Substances 0.000 claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 21
- 238000000605 extraction Methods 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 11
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 10
- 235000009694 Quassia amara Nutrition 0.000 claims abstract description 6
- 229940013788 quassia Drugs 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 151
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 49
- 238000010828 elution Methods 0.000 claims description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 21
- 239000008103 glucose Substances 0.000 claims description 21
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 19
- 239000011347 resin Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- 239000003208 petroleum Substances 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 13
- 239000003463 adsorbent Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 6
- 230000000274 adsorptive effect Effects 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 206010012655 Diabetic complications Diseases 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 241000158615 Quassia Species 0.000 claims 2
- 239000008280 blood Substances 0.000 abstract description 57
- 210000004369 blood Anatomy 0.000 abstract description 57
- 230000000694 effects Effects 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 7
- 240000003085 Quassia amara Species 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000007012 clinical effect Effects 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 25
- 201000001421 hyperglycemia Diseases 0.000 description 22
- 239000000843 powder Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical group NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000469 ethanolic extract Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003472 antidiabetic agent Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 239000002027 dichloromethane extract Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 208000012201 sexual and gender identity disease Diseases 0.000 description 3
- 208000015891 sexual disease Diseases 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 208000035126 Facies Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- -1 LSA-20 Chemical compound 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- LZKVXMYVBSNXER-YZPKDWIXSA-N Glaucarubin Chemical compound O[C@@H]([C@]1(C)[C@@H]23)[C@@H](O)C=C(C)[C@@H]1C[C@@H]1[C@@]43CO[C@@]2(O)[C@H](O)[C@H](C)[C@@H]4[C@@H](OC(=O)[C@@](C)(O)CC)C(=O)O1 LZKVXMYVBSNXER-YZPKDWIXSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001093962 Simaroubaceae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a use of Eurycoma longifolia Jack in preparation of drugs or health products for prevention and/or treatment on high blood sugar diseases The Eurycoma longifolia Jack comprises quassia Eurycoma longifolia Jack or its decoction pieces or extract product. The invention provides an assistant hypoglycemic or hypoglycemic composition. The composition contains a Eurycoma longifolia Jack medical material or its decoction pieces or extract product. The Eurycoma longifolia Jack medical material or its decoction pieces or extract product or preparation can be used for preventing or treating high blood sugar diseases such as diabetes, can produce good treatment effects in short time, can be used as a health food and has high safety. The preparation method provided by the invention has simple processes. Through conventional extraction separation processes, a product with clinical effects is obtained.
Description
Technical field
The present invention relates to medical art, be used for preventing and/or treating hyperglycemic disorder in particular to a kind of Eurycoma longifolia medical material or its extract, be used in particular for preventing and/or treating diabetes.
Background technology
Hyperglycemic disorder is as the term suggests be that content sugared in patient's blood continues to exceed normal level for a long time.Under normal circumstances, by hormonal regulation and this two large regulating system of neuroregulation, human body can guarantee that the source of blood glucose and outlet keep balancing, make blood glucose maintain certain level.But under the combined effect of inherited genetic factors and environmental factors (as irrational meals, obesity etc.), two large regulatory functions get muddled, and just there will be the rising of blood sugar level.
Short time, disposable hyperglycemia to human body without grievous injury.Such as under stress state or excited, high-pressure time, of short duration hyperglycemia can be there is; Once to take food a large amount of saccharides, also can occur of short duration hyperglycemia; Subsequently, blood sugar level recovers normal gradually.But long-term hyperglycemia can make each histoorgan generation pathological changes of whole body, causes the generation of acute and chronic complication.As pancreatic function exhaustion, lose water and rock-soil coupling, malnutrition, resistance decline, impaired renal function, neuropathy, retinopathy etc.Long-time blood glucose is too high by the environment of heavy damage human body, causes a series of biochemical pathological change, affects the function of each internal organs, thus cause a series of complication.
Therefore, be necessary to develop can safety, effectively by glucostasis at normal level, and can prevent or delay medicine that complication occurs or health product.
The formal name used at school of Eurycoma longifolia (Tongkat Ali) is Eurycoma longifolia Jack, another name: Malaysian Radix Ginseng, unipods are loose, belong to Simarubaceae (Simaroubaceae) plant.Eurycoma longifolia is a kind of poky Tropical rain forest shrub plant, and be mainly distributed in the ground such as Burma, Thailand, Malaysia, Vietnam, also there is distribution in China Hainan Island.Its function with cure mainly as the heat that disappears, cut cruel, blood pressure lowering, dysentery relieving, tonification, dampness removing jaundice eliminating, tonifying YANG, contact pruritus, cure mainly the diseases such as hypertension, scabies, jaundice, the dry carbuncle of blood, waist foot are unable, liver energy stagnation type sexual impotence, skin pruritus.Be usually used in the diseases such as treatment malaria, dysentery, oral ulcer, orangutan heat are red, headache, also there is the effect strengthening male's sexual.Recent research shows, the Ramulus Et Folium Picrasmae alkali (quassinoids) extracted from this plant also has good antitumor and AntiHIV1 RT activity effect.
Prior art more discloses Eurycoma longifolia or its extract is improving the pharmacologically active in male sexual disorder.Such as, disclose the effect that Eurycoma longifolia extract product has treatment male sexual disorder in EP1952816 European patent.Disclosing Eurycoma longifolia polar organic solvent extract in MY2006PI03783 Malaysian Patent for promoting that sperm grows, improving sperm quality and treating effect of the aspect such as infertile.No. JP2012092108 Japanese patent discloses the extract prepared for raw material with the root of Eurycoma longifolia medical material and is used as medicine, be prepared into external preparation and can treat male sexual disorder.The CN102430038 Chinese patent compositions disclosed containing Eurycoma longifolia medical material has the effect improving testosterone content.
In addition, No. US2007224300 U.S. patents discloses during a kind of compositions be made up of Eurycoma longifolia extract product and citrus peel extract can be used for accelerating loss of weight and help diet keeper to lose weight and maintains high ability.MY142166 Malaysian Patent discloses a kind of chemically reactive substance extracted from Eurycoma longifolia and can be used for treating fat and relevant to obesity disease, described chemically reactive substance comprises chemical composition: quassinoid, 13 (21)-epoxyeurycomanone.
But, there is not yet the relevant report prevented and/or treated Eurycoma longifolia being applied to hyperglycemia relevant disease up to now, more have no the relevant report that it is applied to diabetes mellitus prevention and/or treatment.
Summary of the invention
In order to solve problems of the prior art, the invention provides a kind of safe and effective medicine or health product preventing and/or treating hyperglycemic disorder, it is specially adapted to prevent and/or treat diabetes.Meanwhile, a kind of new medical value or the health care of Eurycoma longifolia is opened up.
Therefore, the object of the present invention is to provide a kind of novelty teabag of Eurycoma longifolia, namely for preventing and/or treating hyperglycemic disorder.Meanwhile, the present invention also aims to the health product finding a kind of new hypoglycemic drug safely and effectively or auxiliary hyperglycemic, providing a kind of new medication select or provide a kind of new health product for preventing and/or treating hyperglycemic disorder clinically.
For achieving the above object, the invention provides Eurycoma longifolia for the preparation of the application prevented and/or treated in the medicine of hyperglycemic disorder or health product.
The example of hyperglycemic disorder of the present invention includes but not limited to: diabetes, diabetic complication, diabetic syndrome, carbohydrate metabolism disturbance and glucose tolerance reduce.
Eurycoma longifolia of the present invention comprises Eurycoma longifolia medical material or its decoction pieces or its extract or their combination in any, and described Eurycoma longifolia medical material can be its position on the ground, and also can be its root, can also be both mixture.In an instantiation, Eurycoma longifolia medical material of the present invention is the root of quassia Eurycoma longifolia (Eurycoma longifolia Jack), is preferably dry root.Described Eurycoma longifolia decoction pieces can be any type of decoction pieces meeting clinical application demand and drug quality requirement.Described Eurycoma longifolia extract product can be with medical material or decoction pieces for raw material, the extract prepared with water or other solvent extraction be applicable to.In an instantiation, Eurycoma longifolia extract product of the present invention is water extract and/or the extract with water miscible solvent, such as with described Eurycoma longifolia medical material or decoction pieces, preferably with the root of Eurycoma longifolia for raw material, use water and/or carry out extracting obtained extract with water miscible solvent.Describedly refer to the solvent that can mix with arbitrary proportion with water with water miscible solvent, such as methanol, ethanol, propanol, formic acid, acetic acid, acetonitrile, acetone or oxolane.Describedly be preferably ethanol or acetone with water miscible solvent.
In some instantiations, Eurycoma longifolia extract product is by any one preparation in 3 kinds of extracting method below:
I. get Eurycoma longifolia medical material, extract with water and/or with water miscible solvent, obtain extracting solution, by obtained extracting solution through concentrated, dry;
II. get Eurycoma longifolia medical material, extract with water and/or with water miscible solvent, obtain extracting solution, by obtained extracting solution through concentrated, gained concentrated solution is crossed macroporous adsorptive resins; With 0-99% ethanol, gradient elution is carried out to macroporous adsorbent resin successively, collect eluate, concentrated, dry;
III. get Eurycoma longifolia medical material, extract with water and/or with water miscible solvent, obtain extracting solution, by obtained extracting solution through concentrated, by gained concentrated solution petroleum ether, dichloromethane, ethyl acetate or n-butanol extraction, collect petroleum ether, dichloromethane, ethyl acetate or butanol extraction liquid, concentrated, dry.
Wherein, the step of described macroporous adsorbent resin gradient elution is preferably: the ethanol elution removing impurity by concentration being first 0-40%, be the ethanol of 45-55% and concentration by concentration be respectively again the ethanol elution of 85-99%, collect ethanol elution that concentration is 45-55% respectively and concentration is the ethanol elution of 85-99%.
Described gradient elution step is more preferably: first use 5% ethanol elution colourless to eluent, then use 50% ethanol elution, finally use 95% ethanol elution, collect 50% ethanol elution or 95% ethanol elution.
Another object of the present invention is to provide a kind of auxiliary hyperglycemic or hypoglycemic composition, and it comprises Eurycoma longifolia medical material, Eurycoma longifolia decoction pieces, Eurycoma longifolia extract product or their combination in any.A such as hypoglycemic pharmaceutical composition, it comprises the Eurycoma longifolia medical material or its decoction pieces or its extract for the treatment of effective dose, and it can also comprise other active blood sugar-lowering substances or pharmaceutically acceptable carrier.Again such as, the invention provides a kind of health composition of auxiliary hyperglycemic, it includes Eurycoma longifolia medical material or its decoction pieces or its extract or its mixture; Similarly, it can also comprise acceptable carrier in other auxiliary hyperglycemic active substances or health product.
In an instantiation, the Eurycoma longifolia medical material used in described compositions is the powder of the root of quassia Eurycoma longifolia (Eurycoma longifolia Jack), is Eurycoma longifolia protogenic medicinal powder; The protogenic medicinal powder of described Eurycoma longifolia, can prepare by the following method:
Get the dry root of Eurycoma longifolia, removing impurity, is ground into 60 ~ 200 object fine powders; Preferred powder is broken into the fine powder that 95% ~ 100% crosses 100 mesh sieves; More preferably the fine powder that 95% ~ 100% crosses 200 mesh sieves is ground into.
In another instantiation, described Eurycoma longifolia extract product is prepared by the root of quassia Eurycoma longifolia (Eurycomalongifolia Jack).
Especially, described Eurycoma longifolia extract product is water extract and/or the extract with water miscible solvent.Describedly refer to the solvent that can mix with arbitrary proportion with water with water miscible solvent, such as methanol, ethanol, propanol, formic acid, acetic acid, acetonitrile, acetone or oxolane, consider extraction efficiency and large safety of producing and cost, be more preferably ethanol.
Eurycoma longifolia extract product of the present invention can be by use water and/or with water mixable solvent extraction Eurycoma longifolia medical material after the mixture that obtains, also can be the extract after the purification obtained after this mixture is further purified.The preparation method that can be exemplified by the present invention obtains, and also can be to be obtained by those skilled in the art's other conventional method thinkable, can also be the Eurycoma longifolia extract product directly bought.As long as can realize the object of the invention, the present invention is not restricted the preparation method of Eurycoma longifolia extract product or source.
In some instantiations, described Eurycoma longifolia extract product is prepared from by following method:
1) extract: get Eurycoma longifolia pulverizing medicinal materials and become coarse powder, such as, cross 20 orders, after extracting with water, ethanol or aquiferous ethanol, filter, concentrated, obtain concentrated solution;
2) purification: get concentrated solution, then after conventional separation methods process, to obtain final product.
Wherein, described conventional separation methods comprises macroporous adsorbent resin partition method, organic solvent extraction partition method or its combination.
Described macroporous adsorbent resin partition method is after being dissolved by crude extract dilute with water, go up macroporous adsorptive resins again, then ethanol gradient elution is used, such as first with the ethanol elution removing impurity that concentration is 0-40%, be the ethanol of 45-55% and concentration by concentration be respectively again the ethanol elution of 85-99%, collect the ethanol elution thing that ethanol elution thing that concentration is 45-55% and concentration are 85-99% respectively.
Described organic solvent extractionprocess is by after crude extract aqueous dispersion, then extracts successively with petroleum ether, dichloromethane, ethyl acetate or n-butyl alcohol, collects organic facies respectively, i.e. petroleum ether, dichloromethane, ethyl acetate or n-butyl alcohol phase, concentrated, dry.
Further, described Eurycoma longifolia extract product is prepared from by following method:
1) extract: get Eurycoma longifolia pulverizing medicinal materials and become coarse powder, such as, cross 20 orders, after water extraction, filter, concentrated, obtain concentrated solution;
2) purification: get concentrated solution, adopts macroporous adsorbent resin to carry out adsorption-edulcoration, first uses 5% ethanol elution to colourless, then uses 50% ethanol elution, finally use 95% ethanol elution, collect 50% ethanol elution, dry, obtains Eurycoma longifolia extract product; Or
1) extract: get Eurycoma longifolia pulverizing medicinal materials and become coarse powder, such as, cross 20 orders, after 95% ethanol extraction, filter, concentrated, obtain concentrated solution;
2) purification: get concentrated solution, with water dissolution, and then with any one organic extractant solution in petroleum ether, dichloromethane, ethyl acetate or n-butyl alcohol, collects organic facies, concentrated, is drying to obtain Eurycoma longifolia extract product.
The present invention also provides a kind of method preparing described auxiliary hyperglycemic or hypoglycemic composition, Eurycoma longifolia medical material or its decoction pieces or its extract are mixed with pharmaceutically acceptable carrier, it is characterized in that, the preparation method of described Eurycoma longifolia extract product comprises the steps:
1) get Eurycoma longifolia medical material, extract with water and/or with water miscible solvent, obtain extracting solution, by obtained extracting solution through concentrated, dry; Or
2) step 1) gained extracting solution is directly gone up macroporous adsorptive resins, or go up macroporous adsorptive resins again by after first for step 1) gained extracting solution dilute with water; With 0-99% ethanol, gradient elution is carried out to macroporous adsorbent resin successively, collect eluate, concentrated, dry; Or
3) by step 1) gained extracting solution petroleum ether, dichloromethane, ethyl acetate or n-butanol extraction, petroleum ether, dichloromethane, ethyl acetate or n-butyl alcohol phase is collected, concentrated, dry.
Eurycoma longifolia extract product of the present invention can be the crude extract of step 1) gained, also can be through step 2) or step 3) purification after the high extract of the purity of gained; Can also be successively through step 1), 2) and 3) the higher extract of purity after process.
Preferably, described macroporous adsorbent resin gradient elution is first with the ethanol elution removing impurity that concentration is 0-40%, be the ethanol of 45-55% and concentration by concentration be respectively again the ethanol elution of 85-99%, collect the ethanol elution thing that ethanol elution thing that concentration is 45-55% and concentration are 85-99% respectively.
More preferably, described gradient elution step is: first use 5% ethanol elution colourless to eluent, then use 50% ethanol elution, finally use 95% ethanol elution, collects 50% ethanol elution or 95% ethanol elution, concentrated, dry, obtains Eurycoma longifolia extract product.
Wherein, described macroporous adsorbent resin is non-polar resin or low polar resin, preferred DA-201, D-101, LSA-20, HP-10 or AB-8 type macroporous adsorbent resin.
Above-described extraction, can adopt large production in modern technologies above to extract, as Soakage extraction, seepage pressure effects, reflux, extract, microwave radiation exaraction, supersound extraction, supercritical extraction etc. with pharmaceutically acceptable various extracting method; Extracting solution concentrates, and normal pressure can be adopted to concentrate, also can adopt concentrating under reduced pressure etc.; Concentrated solution is dry, and the drying of hot air drying, vacuum decompression, microwave (vacuum) drying, spraying dry etc. can be adopted to produce upper and pharmaceutically acceptable various drying mode greatly.
The present invention also provides a kind of preparation for preventing and/or treating hyperglycemic disorder, and described preparation contains Eurycoma longifolia medical material or its decoction pieces or its extract.Wherein Eurycoma longifolia medical material is preferably powder morphology, i.e. Eurycoma longifolia protogenic medicinal powder.Described Eurycoma longifolia extract product can be water and/alcohol crude extract, also can be the extract after the purification of crude extract gained after being further purified, such as the eluate of gained after macroporous adsorbent resin is separated, preferably 50% ethanol elution thing; Or after organic solvent extraction the extract of gained, preferred n-butyl alcohol extract and dichloromethane extract.
Preparation of the present invention can be that the former medicine fecula of Eurycoma longifolia directly makes the acceptable preparation clinically such as powder, granule, capsule, tablet or pill; Also can be make acceptable preparation clinically, such as tablet, pill or granule etc. after protogenic medicinal powder is added pharmaceutically acceptable carrier.With the preparation that protogenic medicinal powder is used as medicine, taking dosage day is that preferably 10.8 ~ 20g/d, is more preferably 14.4g/d by raw medicinal herbs 7.2 ~ 30g/d.
Preparation of the present invention also can be used as medicine with the extract of Eurycoma longifolia, directly or make the acceptable preparation clinically such as pill, granule, oral liquid, capsule, tablet, syrup, injection after adding pharmaceutically acceptable carrier.Be preferably oral formulations, such as pill, granule, oral liquid, capsule or tablet.
Preparation of the present invention can also be used as medicine with Eurycoma longifolia decoction pieces, or Eurycoma longifolia and other medical materials, such as the composition such as Radix Ginseng, Rhizoma Coptidis hypoglycemic compound preparation.
In some instantiations, described pharmaceutically acceptable carrier can be the pharmaceutically acceptable carrier that the conventional formulations such as the oral or injection of any preparation are conventional, such as: sucrose, dextrin, starch, lactose, mannitol, xylitol, chitosan, chitosan, SHUANGQITANG, Pulvis Talci, sodium carboxymethyl cellulose (CMS-Na), microcrystalline Cellulose (MCC), micropowder silica gel, alpha-cyclodextrin (α-CD), beta-schardinger dextrin-(β-CD), polyvinylpyrrolidone (polyvidone), hydroxypropyl cellulose, Polyethylene Glycol (PEG).Also can add dyestuff, such as iron oxide yellow and/or iron oxide red, and/or titanium dioxide, its objective is and match colors.Above-mentioned pharmaceutically acceptable carrier can be used alone, also can conbined usage.As long as persons of ordinary skill in the art may appreciate that and can realize object of the present invention, any pharmaceutically acceptable adjuvant all can be used for preparing invention formulation.
Preparation of the present invention can be used for preventing and treating hyperglycemia relevant disease, such as diabetes.
On the other hand, the invention provides a kind of health product of auxiliary hyperglycemic, it contains Eurycoma longifolia medical material or its decoction pieces or its extract.The adjuvant that described health product add and preparation technique are all this area routines, and the present invention does not limit, as long as meet the demand of respective quality standard or Clinical practice.
The obtainable beneficial effect of the present invention at least comprises:
1. the invention provides a kind of new clinical value or the health value of Eurycoma longifolia medical material, and protogenic medicinal powder, crude extract can play hypoglycemic curative effect;
2. Eurycoma longifolia provided by the invention and preparation thereof are used for prevention or treatment hyperglycemic disorder, such as diabetes, can obtain better therapeutic effect within shorter service time, and safe without toxic side effect;
3. preparation method provided by the present invention is simple, and adopt conventional extraction and separation process can obtain the product with clinical efficacy, the industry of being convenient to is applied.
Detailed description of the invention
For making the present invention easier to understand, describe the present invention in detail below in conjunction with embodiment, these embodiments only play illustrative effect, are not limited to range of application of the present invention, NM specific experiment method in the following example, conveniently experimental technique carries out usually.
Not specified part, " % " represents percentage by weight.
Embodiment
The preparation of embodiment 1 Eurycoma longifolia water extract
Get the root of Eurycoma longifolia medical material, pulverize, take about 20g, by 10 times of water gaging reflux, extract, three times, extraction time is respectively 2h, 1.5h, 1.5h, and temperature is about 90 DEG C, and merge extractive liquid, is evaporated to 10ml, and specification is 2:1(g/ml).
The preparation of embodiment 2 Eurycoma longifolia ethanol extract
Get the root of Eurycoma longifolia medical material, pulverize, take about 20g, with 10 times amount 95% alcohol reflux three times, extraction time is respectively 2h, 1.5h, 1.5h, and temperature is about 70 DEG C, and merge extractive liquid, is evaporated to 10ml, and specification is 2:1(g/ml).
The preparation of embodiment 3 Eurycoma longifolia petroleum ether, dichloromethane, ethyl acetate, n-butyl alcohol extract
Prepare Eurycoma longifolia ethanol extract 400g by the method for embodiment 2, add water to be dispersed to and dissolve completely, extract with petroleum ether, dichloromethane, ethyl acetate, n-butyl alcohol successively.Concentrating under reduced pressure each several part extract, and the water layer after concentrated extraction, obtain each several part extractum.The yield of each extract and character are in table 1.
The character of each extract of table 1 Eurycoma longifolia and yield
| Lot number | Sample ID | Example weight (g) | Extract consumption (g) | The rate of extract (%) | Appearance character explanation |
| 20080522 | Petroleum ether portion | 8 | 400 | 2 | Yellow oil |
| 20080522 | Dichloromethane extraction part | 41 | 400 | 10.25 | Brown color paste |
| 20080522 | Ethyl acetate extraction part | 50 | 400 | 12.5 | Yellow-brown solid |
| 20080522 | N-butanol portion | 53 | 400 | 13.25 | Orange-yellow paste |
| 20080522 | Water section after extraction | 251 | 400 | 62.75 | Brown solid |
The preparation of embodiment 4 Eurycoma longifolia water extract tablet
Eurycoma longifolia water extract is prepared according to the method for embodiment 1, get 400ml wherein, after adding starch 50g, dextrin 50g mix homogeneously, the hypromellose adding 2% carries out soft material processed as binding agent, granulate dry, add carboxymethyl starch sodium and lubricant 0.5% magnesium stearate of disintegrating agent 4%, mix homogeneously, tabletting, to obtain final product.Every sheet, containing described Eurycoma longifolia water extract 0.4ml, is converted to medical material, and every sheet is about 1.6g, oral administration, every day 3 times, each 3 containing Eurycoma longifolia primary crude drug.
The preparation of embodiment 5 Eurycoma longifolia n-butanol extraction composition injection
N-butyl alcohol extract 50g prepared by Example 3, inject and make dissolving in right amount with water, 0.02% active carbon adding amount of preparation stirs 5-10min, filters, filtrate is diluted to about 5L, adding sodium chloride regulates osmotic pressure to isotonic, adjust pH to 7.5-8.0, ultrafiltration, embedding becomes 500 (10ml/ props up), sterilizing, packaging, obtains Eurycoma longifolia n-butanol extraction composition injection.Drug administration by injection, every day 2 times, each 1.
Embodiment 6 Eurycoma longifolia water extract, ethanol extract are to the blood sugar reducing function of model induced by alloxan hyperglycemia mice
Adopt random, control experiment, blank, model group, positive control insoral group and Eurycoma longifolia water extract, the effect of ethanol extract group to model induced by alloxan hyperglycemia mouse blood sugar are as shown in table 2.
Impact on model induced by alloxan hyperglycemia mouse blood sugar in 7 days, 14 days after table 2 Eurycoma longifolia water, alcohol extract medicine
Note: compare with model control group,
* *p<0.001,
*p<0.01,
*p<0.05; Compare with blank group,
△ △ △p<0.00
From table 2, before administration, each modeling group of blood glucose value compares with blank group, and mouse blood sugar value obviously raises, and difference has significance (P<0.001), meets random packet requirement.
Administration 7 days blood glucose values: model control group compares with blank group, and mouse blood sugar value obviously raises, difference has significance (P<0.001); Insoral group compares with model control group, and mouse blood sugar value obviously reduces, and difference has significance (P<0.001), and blood sugar lowering rate is 49.48%; Eurycoma longifolia water extract group compares with model control group, and mouse blood sugar value obviously reduces, and difference has significance (P<0.05), and blood sugar lowering rate is 24.71%; Eurycoma longifolia ethanol extract group compares with model control group, and mouse blood sugar value obviously reduces, and difference has significance (P<0.01), and blood sugar lowering rate is 35.00%.
Administration 14 days blood glucose values: model control group compares with blank group, and mouse blood sugar value obviously raises, difference has significance (P<0.001); Insoral group compares with model control group, and mouse blood sugar value obviously reduces, and difference has significance (P<0.001), and blood sugar lowering rate is 54.82%; Eurycoma longifolia water extract group compares with model control group, and mouse blood sugar value obviously reduces, and difference has significance (P<0.05), and blood sugar lowering rate is 16.01%; Eurycoma longifolia ethanol extract group compares with model control group, and mouse blood sugar value obviously reduces, and difference has significance (P<0.001), and blood sugar lowering rate is 42.35%.
Blank, model group and each administration group (positive control insoral group and Eurycoma longifolia water extract, ethanol extract group) are as shown in table 3 on the impact of the body weight of model induced by alloxan hyperglycemia mice.
Impact on model induced by alloxan hyperglycemia Mouse Weight in 7 days, 14 days after table 3 Eurycoma longifolia water, alcohol extract medicine
Note: compare with blank group,
△p<0.05.
From table 3, before administration, each administration group compares with blank group, and Mouse Weight obviously declines, and difference has significance (P<0.05); Compare between each administration group, Mouse Weight without significant change, unknown significance difference (P>0.05).
After administration 7 days, model control group compared with blank group, and Mouse Weight obviously declines, and difference has significance (P<0.05); Other each administration group compares with model control group, and Mouse Weight, without significant change, has no significant difference (P>0.05).
After administration 14 days, model control group compared with blank group, and Mouse Weight obviously declines, and difference has significance (P<0.05); Other each administration group compares with model control group, and Mouse Weight is in a slight decrease, but has no significant difference (P>0.05).
To sum up, Eurycoma longifolia water, alcohol extract (10g crude drug/kg) have obvious blood sugar reducing function to the hyperglycemia mice of model induced by alloxan, and wherein the hypoglycemic effect of Eurycoma longifolia alcohol extract (10g crude drug/kg) is better; Eurycoma longifolia water, alcohol extract can suppress model induced by alloxan hyperglycemia Mouse Weight to decline.
Embodiment 7 Eurycoma longifolia extract is to the blood sugar reducing function of model induced by alloxan hyperglycemia mice
Adopt random, control experiment design, it is as shown in table 4 that blank, model group, positive control insoral group and Eurycoma longifolia respectively extract position and petroleum ether group, dichloromethane group, ethyl acetate group, n-butyl alcohol group and water section group and the effect of commercially available Eurycoma longifolia extract product group to model induced by alloxan hyperglycemia mouse blood sugar.
Impact on model induced by alloxan hyperglycemia mouse blood sugar in 7 days, 14 days after the administration of table 4 Eurycoma longifolia extract
Note: compare with model control group,
* *p<0.001,
*p<0.01,
*p<0.05; Compare with blank group,
△ △ △p<0.001.
From table 4, blood glucose value before medicine: each modeling group compares with blank group, and mouse blood sugar value obviously raises, difference has significance (P<0.001), meets random packet requirement.
Administration 7 days blood glucose values: model control group compares with blank group, and the blood glucose value of mice obviously raises, difference has significance (P<0.001); Insoral group compares with model control group, and the blood glucose value of mice obviously reduces, and difference has significance (P<0.001), and blood sugar lowering rate is 53.09%; The commercially available extract group of Eurycoma longifolia, Eurycoma longifolia n-butyl alcohol extract group, Eurycoma longifolia dichloromethane extract group compare with model control group, the blood glucose value of mice obviously reduces, difference has significance (P<0.05 ~ P<0.001), and blood sugar lowering rate is respectively 21.98%, 28.76%, 31.22%; Eurycoma longifolia petroleum ether extraction thing group, Eurycoma longifolia acetic acid ethyl ester extract group, Eurycoma longifolia water section group compare with model control group, the blood glucose value of mice has reduction trend in various degree, but all do not occur significant difference (P>0.05), blood sugar lowering rate is respectively 21.69%, 16.43%, 13.92%.
Administration 14 days blood glucose values: model control group compares with blank group, and the blood glucose value of mice obviously raises, difference has significance (P<0.001); Insoral group compares with model control group, and the blood glucose value of mice obviously reduces, and difference has significance (P<0.001), and blood sugar lowering rate is 50.16%; The commercially available extract group of Eurycoma longifolia, Eurycoma longifolia dichloromethane extract group, Eurycoma longifolia n-butyl alcohol extract group, Eurycoma longifolia water section group compare with model control group, the blood glucose value of mice obviously reduces, difference has significance (P<0.05 ~ P<0.01), and blood sugar lowering rate is respectively 23.15%, 25.15%, 23.49%, 23.78%; Eurycoma longifolia petroleum ether extraction thing group, Eurycoma longifolia acetic acid ethyl ester extract group compare with model control group, the blood glucose value of mice has reduction trend in various degree, but all do not occur significant difference (P>0.05), blood sugar lowering rate is respectively 15.13%, 15.79%.
Blank, model group and each administration group (positive control insoral group and Eurycoma longifolia respectively extract position group, commercially available Eurycoma longifolia extract product group) are as shown in table 5 on the impact of model induced by alloxan hyperglycemia Mouse Weight.
Impact on model induced by alloxan hyperglycemia Mouse Weight in 7 days, 14 days after the administration of table 5 Eurycoma longifolia extract
Note: compare with blank group,
△p<0.05,
△ △p<0.01.
From table 5, before administration, model control group compares with blank group, and Mouse Weight obviously declines, and difference has significance (P<0.01); Each administration group compares with model control group, Mouse Weight without significant change, unknown significance difference (P>0.05).
After administration 7 days, model control group compared with blank group, and Mouse Weight obviously declines, and difference has significance (P<0.01); Each administration group compares with model control group, Mouse Weight without significant change, unknown significance difference (P>0.05).
After administration 14 days, model control group compared with blank group, and Mouse Weight obviously declines, and difference has significance (P<0.05); Each administration group compares with model control group, Mouse Weight without significant change, unknown significance difference (P>0.05).
To sum up, the commercially available extract of Eurycoma longifolia, Eurycoma longifolia n-butyl alcohol extract and Eurycoma longifolia dichloromethane extract all have significant blood sugar reducing function to model induced by alloxan hyperglycemia mice, Eurycoma longifolia petroleum ether extract group and acetic acid second group extract group also show blood sugar lowering trend, but do not occur significant difference.The each extract group of Eurycoma longifolia all can suppress model induced by alloxan hyperglycemia Mouse Weight to decline.
Above-mentioned the pharmacological results shows: Eurycoma longifolia water extract, alcohol extract and each extract all can reduce blood glucose effectively, suppresses model induced by alloxan hyperglycemia Mouse Weight to decline.Prompting Eurycoma longifolia is to the hyperglycemia relevant disease of the mankind, and such as diabetes, diabetic complication, diabetic syndrome or glucose tolerance reduction etc. have the effect of preventing and/or treating.
Embodiment 8 is containing the hypoglycemic compound of Eurycoma longifolia
Concrete prescription is composed as follows:
Eurycoma longifolia 20g, Radix Ginseng 15g, Rhizoma Coptidis 5g
After each taste medicine is mixed in proportion above, add 500-600ml water, decoct 30min, filter, medicinal residues decoct twice again, add 400-500ml water at every turn, decoct 30min.Filter, merge three filtrates.Sooner or later respectively once, oral.
Embodiment 9 is containing the hypoglycemic compound of Eurycoma longifolia
Eurycoma longifolia 30g, Cortex Cinnamomi 5g, Radix Rehmanniae 10g, Rhizoma Anemarrhenae 10g, Flos Carthami 5g
After each taste medicine is mixed in proportion above, add 800-1000ml water, decoct 30min, filter, medicinal residues decoct twice again, add 600-800ml water at every turn, decoct 30min.Filter, merge three filtrates.Sooner or later respectively once, oral.
The present invention can not exhaustive all hypoglycemic compounds with Eurycoma longifolia prescription; here several hypoglycemic compound containing Eurycoma longifolia medical material is only exemplarily illustrated; be intended to protection Eurycoma longifolia as a herb for hypoglycemic compound preparation; it can form compound preparation with other medical materials or components compatibility and be applied to clinical, and can be blood sugar lowering or assistant hypoglycemic clinically provides a kind of new medication to select.
The above is only the preferred embodiments of the present invention, not any pro forma restriction is done to the present invention, although the present invention discloses as above with preferred embodiment, but and be not used to limit the present invention, any those skilled in the art, not departing from the scope of technical solution of the present invention, make a little change when the technology contents of above-mentioned announcement can be utilized or be modified to the Equivalent embodiments of equivalent variations, in every case be the content not departing from technical solution of the present invention, according to any simple modification that technical spirit of the present invention is done above embodiment, equivalent variations and modification, all still belong in the scope of technical solution of the present invention.
Claims (10)
1. Eurycoma longifolia is for the preparation of the application prevented and/or treated in hyperglycemic disorder medicine or health product.
2. application according to claim 1, is characterized in that, described hyperglycemic disorder is that diabetes, diabetic complication and glucose tolerance reduce.
3. application according to claim 1 and 2, is characterized in that, described Eurycoma longifolia is the root of quassia Eurycoma longifolia (Eurycoma longifolia Jack) or its decoction pieces or its extract.
4. application according to claim 3, is characterized in that, described Eurycoma longifolia extract product is water extract and/or the extract with water miscible solvent; Describedly be preferably ethanol or acetone with water miscible solvent.
5. application according to claim 3, is characterized in that, described Eurycoma longifolia extract product is by any one preparation in 3 kinds of extracting method below:
I. get Eurycoma longifolia medical material, extract with water and/or with water miscible solvent, obtain extracting solution, by obtained extracting solution through concentrated, dry;
II. get Eurycoma longifolia medical material, extract with water and/or with water miscible solvent, obtain extracting solution, by obtained extracting solution through concentrated, gained concentrated solution is crossed macroporous adsorptive resins; With 0-99% ethanol, gradient elution is carried out to macroporous adsorbent resin successively, collect eluate, concentrated, dry;
III. get Eurycoma longifolia medical material, extract with water and/or with water miscible solvent, obtain extracting solution, by obtained extracting solution through concentrated, by gained concentrated solution petroleum ether, dichloromethane, ethyl acetate or n-butanol extraction, collect petroleum ether, dichloromethane, ethyl acetate or butanol extraction liquid, concentrated, dry.
6. application according to claim 5, it is characterized in that, the step of described macroporous adsorbent resin gradient elution is: the ethanol elution removing impurity by concentration being first 0-40%, be the ethanol of 45-55% and concentration by concentration be respectively again the ethanol elution of 85-99%, collect ethanol elution that concentration is 45-55% respectively and concentration is the ethanol elution of 85-99%.
7. application according to claim 6, is characterized in that, described gradient elution step is: first use 5% ethanol elution colourless to eluent, then use 50% ethanol elution, finally use 95% ethanol elution, collects 50% ethanol elution or 95% ethanol elution.
8. auxiliary hyperglycemic or a hypoglycemic composition, it comprises Eurycoma longifolia medical material, Eurycoma longifolia decoction pieces, Eurycoma longifolia extract product or their combination in any.
9. compositions according to claim 8, is characterized in that, described Eurycoma longifolia medical material is the root of quassia Eurycoma longifolia (Eurycoma longifolia Jack); Described Eurycoma longifolia extract product is water extract and/or the extract with water miscible solvent, is describedly preferably ethanol or acetone with water miscible solvent.
10. for preventing and/or treating a preparation for hyperglycemic disorder, it is characterized in that, containing Eurycoma longifolia medical material or its decoction pieces or its extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310612131.0A CN104666373A (en) | 2013-11-27 | 2013-11-27 | Novel use of Eurycoma longifolia Jack |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310612131.0A CN104666373A (en) | 2013-11-27 | 2013-11-27 | Novel use of Eurycoma longifolia Jack |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104666373A true CN104666373A (en) | 2015-06-03 |
Family
ID=53302309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310612131.0A Pending CN104666373A (en) | 2013-11-27 | 2013-11-27 | Novel use of Eurycoma longifolia Jack |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104666373A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362315A (en) * | 2015-12-07 | 2016-03-02 | 常熟求是科技有限公司 | Eurycoma longifolia extract and method for preparing same |
| CN106474167A (en) * | 2015-08-25 | 2017-03-08 | 沈阳药科大学 | Eurycoma longifolia extract product, eurycomanone and its preparation method and application |
| CN106562469A (en) * | 2015-10-07 | 2017-04-19 | 惠州市吉瑞科技有限公司 | Electronic cigarette tobacco liquid |
| CN109567192A (en) * | 2018-11-16 | 2019-04-05 | 湖南朗林生物资源股份有限公司 | A kind of preparation method of Eurycoma longifolia extract product |
| CN111329943A (en) * | 2018-12-19 | 2020-06-26 | 山东理工大学 | A compound herbal preparation with antihyperglycemic and antioxidant effects for treating diabetes |
| CN112584711A (en) * | 2018-08-21 | 2021-03-30 | 日本烟草产业株式会社 | Deep body temperature lowering agent, food, and sleep improving agent |
| US11058737B2 (en) | 2018-10-29 | 2021-07-13 | Biotropics Malaysia Berhad | Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102430038A (en) * | 2011-12-07 | 2012-05-02 | 北京康比特体育科技股份有限公司 | Composition for increasing blood testosterone, preparation containing composition and preparation method of composition |
-
2013
- 2013-11-27 CN CN201310612131.0A patent/CN104666373A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102430038A (en) * | 2011-12-07 | 2012-05-02 | 北京康比特体育科技股份有限公司 | Composition for increasing blood testosterone, preparation containing composition and preparation method of composition |
Non-Patent Citations (3)
| Title |
|---|
| BEAUTY 4著: "《18个超好玩又便宜的出境旅游点》", 31 January 2008, 中国旅游出版社 * |
| RAFIDAH HUSEN,ET AL.: "Screening for antihyperglycaemic activity in several local herbs of Malaysia", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
| RAJEEV BHAT,ET AL.: "Tongkat Ali （Eurycoma longifolia Jack）：A review on its ethnobotany and pharmacological importance", 《FITOTERAPIA》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106474167A (en) * | 2015-08-25 | 2017-03-08 | 沈阳药科大学 | Eurycoma longifolia extract product, eurycomanone and its preparation method and application |
| CN106562469A (en) * | 2015-10-07 | 2017-04-19 | 惠州市吉瑞科技有限公司 | Electronic cigarette tobacco liquid |
| CN105362315A (en) * | 2015-12-07 | 2016-03-02 | 常熟求是科技有限公司 | Eurycoma longifolia extract and method for preparing same |
| CN105362315B (en) * | 2015-12-07 | 2020-03-20 | 常熟求是科技有限公司 | Eurycoma longifolia extract and preparation method thereof |
| CN112584711A (en) * | 2018-08-21 | 2021-03-30 | 日本烟草产业株式会社 | Deep body temperature lowering agent, food, and sleep improving agent |
| US11058737B2 (en) | 2018-10-29 | 2021-07-13 | Biotropics Malaysia Berhad | Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females |
| CN109567192A (en) * | 2018-11-16 | 2019-04-05 | 湖南朗林生物资源股份有限公司 | A kind of preparation method of Eurycoma longifolia extract product |
| CN111329943A (en) * | 2018-12-19 | 2020-06-26 | 山东理工大学 | A compound herbal preparation with antihyperglycemic and antioxidant effects for treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102895432A (en) | Prescription and preparation method of rejoicing powder having new dosage form | |
| CN104666373A (en) | Novel use of Eurycoma longifolia Jack | |
| CN104435749B (en) | A kind of dendrobium candidum compound preparation and its preparation method and application | |
| CN105012452A (en) | New application of clausena lansium leaves | |
| CN104225006A (en) | Traditional Chinese medicine composition capable of invigorating Qi and relaxing bowels | |
| CN103705594B (en) | Chinese medicine composition for the treatment of hyperlipemia and preparation method thereof | |
| CN102302673A (en) | Traditional Chinese medicine compound preparation for preventing and treating diabetic nephropathy (DN) | |
| CN102228547B (en) | Application of traditional Chinese medicine composition in preparing medicaments treating pancreatitis and/or cholecystitis | |
| CN102743584A (en) | Traditional Chinese medicine for decreasing blood sugar and preparation method thereof | |
| CN107890528A (en) | A kind of Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN102846879A (en) | Composition for depressing blood fat | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN1899342A (en) | Oral medicine for treating diabetes and its use | |
| CN101167951A (en) | Traditional Chinese medicinal composition for treating diabetes and its preparation method | |
| CN101890063A (en) | Chinese medicament for reducing blood sugar and preparation method thereof | |
| CN101450177A (en) | Traditional Chinese medicine composition with blood sugar reducing function and preparation method thereof | |
| CN102895433A (en) | Prescription and preparation method of forgetfulness treating pill having new dosage form | |
| CN102727627B (en) | Traditional Chinese medicine composition for treating heart failure and preparation method and application thereof | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN101450162A (en) | Traditional Chinese medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN102058771A (en) | Chinese medicine preparation for treating insomnia and preparation method thereof | |
| CN102631415A (en) | Traditional Chinese medicine composite as well as product and application thereof | |
| CN119424562B (en) | A traditional Chinese medicine composition, preparation and application for treating drug-induced renal injury | |
| CN102512481B (en) | Common threewingnut root capsules and application thereof | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 102206, 20 floor, No. 6, life road, Beijing, Changping District, 3 Applicant after: Zhou Yawei Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Applicant before: Zhou Yawei |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100084 HAIDIAN, BEIJING TO: 102206 CHANGPING, BEIJING |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150603 |
|
| WD01 | Invention patent application deemed withdrawn after publication |